Ravgen’s ability to increase the percentage of fetal DNA present in blood from the pregnant mother allows noninvasive prenatal genetic testing for single gene disorders, such as cystic fibrosis and sickle cell anemia. When a pregnant mother and her partner are both carriers for a recessive single gene disorder, they have a 1 in 4 chance of having a baby affected with that genetic condition, or 2 in 4 chance of having a baby that is a carrier.
Ravgen’s noninvasive prenatal single-gene disorder testing is a safer and earlier alternative than invasive tests like chorionic villi sampling (CVS) or amniocentesis. Single gene disorders that can be tested by noninvasive prenatal testing include cystic fibrosis, sickle cell anemia, spinal muscular atrophy, Duchenne muscular dystrophy, and any other single-gene disorder for which the mutation is known. Ravgen welcomes inquiries regarding prenatal tests which are not seen here as our laboratory is continuously moving forward in the field.